UBS Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-115,482
| Closed | -$5.97M | – | 11940 |
|
|
2022
Q3 | $5.97M | Buy |
115,482
+21,145
| +22% | +$874K | ﹤0.01% | 2197 |
|
|
2022
Q2 | $2.34M | Sell |
94,337
-73,833
| -44% | -$1.63M | ﹤0.01% | 3023 |
|
|
2022
Q1 | $4.22M | Buy |
168,170
+156,793
| +1,378% | +$4.41M | ﹤0.01% | 2706 |
|
|
2021
Q4 | $414K | Sell |
11,377
-97,897
| -90% | -$3.44M | ﹤0.01% | 5130 |
|
|
2021
Q3 | $1.87M | Buy |
109,274
+90,544
| +483% | +$1.41M | ﹤0.01% | 3634 |
|
|
2021
Q2 | $251K | Sell |
18,730
-40,368
| -68% | -$994K | ﹤0.01% | 5196 |
|
|
2021
Q1 | $3.03M | Sell |
59,098
-71,430
| -55% | -$4.3M | ﹤0.01% | 3136 |
|
|
2020
Q4 | $8.08M | Buy |
130,528
+129,931
| +21,764% | +$7.44M | ﹤0.01% | 2013 |
|
|
2020
Q3 | $33K | Sell |
597
-142,508
| -100% | -$7.67M | ﹤0.01% | 5939 |
|
|
2020
Q2 | $8.23M | Sell |
143,105
-757,622
| -84% | -$41.2M | ﹤0.01% | 1660 |
|
|
2020
Q1 | $36.2M | Buy |
900,727
+75,135
| +9% | +$3.19M | 0.02% | 692 |
|
|
2019
Q4 | $32.7M | Sell |
825,592
-176,024
| -18% | -$3.09M | 0.01% | 1034 |
|
|
2019
Q3 | $6.79M | Buy |
1,001,616
+605,004
| +153% | +$4.54M | ﹤0.01% | 2097 |
|
|
2019
Q2 | $3.69M | Buy |
396,612
+390,976
| +6,937% | +$4.53M | ﹤0.01% | 2582 |
|
|
2019
Q1 | $78K | Sell |
5,636
-10,298
| -65% | -$118K | ﹤0.01% | 5259 |
|
|
2018
Q4 | $174K | Buy |
15,934
+9,844
| +162% | +$104K | ﹤0.01% | 5074 |
|
|
2018
Q3 | $77K | Buy |
6,090
+4,032
| +196% | +$48.6K | ﹤0.01% | 5810 |
|
|
2018
Q2 | $27K | Buy |
2,058
+808
| +65% | +$9.66K | ﹤0.01% | 6485 |
|
|
2018
Q1 | $17K | Sell |
1,250
-1,015
| -45% | -$10.5K | ﹤0.01% | 6524 |
|
|
2017
Q4 | $13K | Buy |
2,265
+1,646
| +266% | +$11.3K | ﹤0.01% | 6879 |
|
|
2017
Q3 | $5K | Buy |
+619
| New | +$5.15K | ﹤0.01% | 7251 |
|
|
2017
Q1 | – | Sell |
-16,561
| Closed | -$123K | – | 8112 |
|
|
2016
Q4 | $123K | Buy |
16,561
+16,539
| +75,177% | +$119K | ﹤0.01% | 5144 |
|
|
2016
Q3 | $0 | Sell |
22
-1,114
| -98% | -$5.26K | ﹤0.01% | 8038 |
|
|
2016
Q2 | $5K | Buy |
+1,136
| New | +$4.26K | ﹤0.01% | 7153 |
|
|
2016
Q1 | – | Sell |
-2,118
| Closed | -$17K | – | 8366 |
|
|
2015
Q4 | $17K | Sell |
2,118
-636
| -23% | -$4.5K | ﹤0.01% | 6922 |
|
|
2015
Q3 | $17K | Buy |
2,754
+2,524
| +1,097% | +$18.3K | ﹤0.01% | 6868 |
|
|
2015
Q2 | $2K | Sell |
230
-1,271
| -85% | -$10.1K | ﹤0.01% | 8232 |
|
|
2015
Q1 | $11K | Sell |
1,501
-777
| -34% | -$6.07K | ﹤0.01% | 7588 |
|
|
2014
Q4 | $16K | Buy |
+2,278
| New | +$12K | ﹤0.01% | 7974 |
|
Other funds holding CCXI
UBS Group's CCXI Position: Q4 2022 in Review
UBS Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 115,482 shares — an estimated $5.97M sold.
UBS Group first reported a position in CCXI in Q4 2014 and held it in 29 quarters. The position peaked at $36.2M in Q1 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- UBS Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- UBS Group sold 115,482 ChemoCentryx, Inc. shares in Q4 2022, an estimated $5.97M.
- UBS Group first reported a position in ChemoCentryx, Inc. in Q4 2014 and held it in 29 quarters.
- UBS Group's ChemoCentryx, Inc. position peaked at $36.2M in Q1 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.